Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children

Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress th...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulaziz Alolayan, Abdullah S. Aldamegh, Azzah Alkhayrat
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Case Reports in Critical Care
Online Access:http://dx.doi.org/10.1155/2023/8530060
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832559270141362176
author Abdulaziz Alolayan
Abdullah S. Aldamegh
Azzah Alkhayrat
author_facet Abdulaziz Alolayan
Abdullah S. Aldamegh
Azzah Alkhayrat
author_sort Abdulaziz Alolayan
collection DOAJ
description Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.
format Article
id doaj-art-3cff685e1af24152a32dc350f96b0ba0
institution Kabale University
issn 2090-6439
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Case Reports in Critical Care
spelling doaj-art-3cff685e1af24152a32dc350f96b0ba02025-02-03T01:30:25ZengWileyCase Reports in Critical Care2090-64392023-01-01202310.1155/2023/8530060Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in ChildrenAbdulaziz Alolayan0Abdullah S. Aldamegh1Azzah Alkhayrat2Pharmacy DepartmentPediatrics DepartmentPharmacy DepartmentCoronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.http://dx.doi.org/10.1155/2023/8530060
spellingShingle Abdulaziz Alolayan
Abdullah S. Aldamegh
Azzah Alkhayrat
Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
Case Reports in Critical Care
title Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
title_full Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
title_fullStr Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
title_full_unstemmed Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
title_short Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
title_sort use of continuous intravenous anakinra infusion in multisystem inflammatory syndrome in children
url http://dx.doi.org/10.1155/2023/8530060
work_keys_str_mv AT abdulazizalolayan useofcontinuousintravenousanakinrainfusioninmultisysteminflammatorysyndromeinchildren
AT abdullahsaldamegh useofcontinuousintravenousanakinrainfusioninmultisysteminflammatorysyndromeinchildren
AT azzahalkhayrat useofcontinuousintravenousanakinrainfusioninmultisysteminflammatorysyndromeinchildren